H G Schnürch1, S Ackermann2, C D Alt3, J Barinoff4, C Böing5, C Dannecker6, F Gieseking7, A Günthert8, P Hantschmann9, L C Horn10, R Kürzl11, P Mallmann12, S Marnitz13, G Mehlhorn14, C C Hack14, M C Koch14, U Torsten15, W Weikel16, L Wölber17, M Hampl18. 1. ehem. Frauenklinik Lukaskrankenhaus, Neuss. 2. Frauenklinik, Klinikum Darmstadt, Darmstadt. 3. Institut für Diagnostische und Interventionelle Radiologie, Universität Düsseldorf, Düsseldorf. 4. Klinik für Gynäkologie und Geburtshilfe, Markus Krankenhaus, Frankfurt am Main. 5. Katholisches Klinikum Oberhausen, Frauenklinik St. Clemens-Hospital, Oberhausen. 6. Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe der Universität München, Campus Großhadern, München, Munich. 7. Dysplasiezentrum in der Frauenarztpraxis Heussweg, Hamburg. 8. Frauenklinik Luzerner Kantonsspital, Lucerne, Switzerland. 9. Abteilung Gynäkologie und Geburtshilfe, Kreiskliniken Altötting - Burghausen, Altötting. 10. Institut für Pathologie des Universitätsklinikums Leipzig, Leipzig. 11. ehem. Universitätsfrauenklinik Maistraße, Munich. 12. Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe der Universität Köln, Cologne. 13. Klinik und Poliklinik für Radioonkologie und Strahlentherapie der Universität Köln, Cologne. 14. Universitätsfrauenklinik Erlangen, Erlangen. 15. Klinik für Gynäkologie und Zentrum für Beckenbodenerkrankungen, Vivantes Klinikum Neukölln, Berlin. 16. Klinik für Gynäkologie und gynäkologische Onkologie, Universitätsfrauenklinik Mainz, Mainz. 17. Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg. 18. Klinik für Frauenheilkunde und Geburtshilfe des Universitätsklinikums Düsseldorf, Düsseldorf.
Abstract
Purpose: This is an official guideline, published and coordinated by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO, Study Group for Gynecologic Oncology) of the Deutsche Krebsgesellschaft (DKG, German Cancer Society) and the Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG, German Society for Gynecology and Obstetrics). The number of cases with vulvar cancer is on the rise, but because of the former rarity of this condition and the resulting lack of literature with a high level of evidence, in many areas knowledge of the optimal clinical management still lags behind what would be required. This updated guideline aims to disseminate the most recent recommendations, which are much clearer and more individualized, and is intended to create a basis for the assessment and improvement of quality care in hospitals. Methods: This S2k guideline was drafted by members of the AGO Committee on Vulvar and Vaginal Tumors; it was developed and formally completed in accordance with the structured consensus process of the Association of Scientific Medical Societies in Germany (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, AWMF). Recommendations: 1. The incidence of disease must be taken into consideration. 2. The diagnostic pathway, which is determined by the initial findings, must be followed. 3. The clinical and therapeutic management of vulvar cancer must be done on an individual basis and depends on the stage of disease. 4. The indications for sentinel lymph node biopsy must be evaluated very carefully. 5. Follow-up and treatment for recurrence must be adapted to the individual case.
Purpose: This is an official guideline, published and coordinated by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO, Study Group for Gynecologic Oncology) of the Deutsche Krebsgesellschaft (DKG, German Cancer Society) and the Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG, German Society for Gynecology and Obstetrics). The number of cases with vulvar cancer is on the rise, but because of the former rarity of this condition and the resulting lack of literature with a high level of evidence, in many areas knowledge of the optimal clinical management still lags behind what would be required. This updated guideline aims to disseminate the most recent recommendations, which are much clearer and more individualized, and is intended to create a basis for the assessment and improvement of quality care in hospitals. Methods: This S2k guideline was drafted by members of the AGO Committee on Vulvar and Vaginal Tumors; it was developed and formally completed in accordance with the structured consensus process of the Association of Scientific Medical Societies in Germany (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, AWMF). Recommendations: 1. The incidence of disease must be taken into consideration. 2. The diagnostic pathway, which is determined by the initial findings, must be followed. 3. The clinical and therapeutic management of vulvar cancer must be done on an individual basis and depends on the stage of disease. 4. The indications for sentinel lymph node biopsy must be evaluated very carefully. 5. Follow-up and treatment for recurrence must be adapted to the individual case.
Authors: David E Cohn; Farrokh Dehdashti; Randall K Gibb; David G Mutch; Janet S Rader; Barry A Siegel; Thomas J Herzog Journal: Gynecol Oncol Date: 2002-04 Impact factor: 5.482
Authors: John K Chan; Valerie Sugiyama; Huyen Pham; Mai Gu; Joanne Rutgers; Kathryn Osann; Michael K Cheung; Michael L Berman; Philip J Disaia Journal: Gynecol Oncol Date: 2006-11-07 Impact factor: 5.482
Authors: Katharina Röhrmoser; Atanas Ignatov; Michael Gerken; Olaf Ortmann; Monika Klinkhammer-Schalke; Thomas Papathemelis Journal: J Cancer Res Clin Oncol Date: 2022-02-18 Impact factor: 4.553
Authors: Eike Burandt; Niclas C Blessin; Ann-Christin Rolschewski; Florian Lutz; Tim Mandelkow; Cheng Yang; Elena Bady; Viktor Reiswich; Ronald Simon; Guido Sauter; Sven Mahner; Nikolaus de Gregorio; Rüdiger Klapdor; Matthias Kalder; Elena I Braicu; Sophie Fürst; Maximilian Klar; Hans-Georg Strauß; Katharina Prieske; Linn Wölber Journal: Cancers (Basel) Date: 2022-08-31 Impact factor: 6.575
Authors: Michael P Lux; Sonja Wasner; Julia Meyer; Lothar Häberle; Carolin C Hack; Sebastian Jud; Alexander Hein; Marius Wunderle; Julius Emons; Paul Gass; Peter A Fasching; Sainab Egloffstein; Jessica Krebs; Yesim Erim; Matthias W Beckmann; Christian R Loehberg Journal: Breast Care (Basel) Date: 2020-08-05 Impact factor: 2.268